A wheelchair directed by the blinks of your eye…

https://j.people.com.cn/n3/2026/0203/c95952-20422094.html

A professor at Qingdao University in Shandong Province has developed a groundbreaking system that generates electricity when people blink, supplying power to glasses that allow patients with amyotrophic lateral sclerosis (ALS) to control their wheelchairs simply by moving their eyes.

With conventional eye tracking devices, patients who wanted to operate a wheelchair and move around had to wear a heavy device on their head and be connected to a long electrical cord. Furthermore, alarms of low battery levels did discouraging patients from moving around on their own.

The eye tracking system of the team generates and supplies electricity by attaching dimethylpolysiloxane (PDMS)  to the surface of the user’s eyeball like a contact lens, creating a “micro-friction generator.” When the user blinks or moves their eyeball, friction occurs between the eyeball and PDMS, continuously generating electricity.

In an eyeglass frame worn by the user, transparent electrodes made of indium tin oxide are embedded, acting as a transducer. The transparent electrodes precisely track the distribution and changes of electric charge through electrostatic induction and convert it into a recognizable electrical signal in real time. This signal is then transmitted to an external device via a control circuit, ultimately enabling highly precise control.

Before this technology can leave the lab and be widely applied, however, a series of hurdles must be overcome for industrialization.

An illustration of controlling a wheelchair through blinking and eye movements (photo courtesy of interviewee).

more insights

https://www.sciencedirect.com/journal/green-carbon

Green Carbon has received its first Impact Factor of 14.2 in the 2025 Journal Citation Reports (JCR) released by Clarivate on June 17, 2026. This places Green Carbon in Q1 in both the “Engineering, Chemical” category (Ranked 10/183) and the “Green & Sustainable Science & Technology” category (Ranked 8/114). Achieving this in less than three years since its launch is a testament to the journal’s academic quality, rigorous publishing standards, and growing international influence.

https://english.news.cn/20260606/de8eff009a94407c8eeeb1fdab13d675/c.html

https://www.cell.com/cell/abstract/S0092-8674(26)00571-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426005714%3Fshowall%3Dtrue

A joint research led by the CAS Institute of Oceanology in collaboration with the Hong Kong-based Chinese University of Hong Kong and Northwestern Polytechnical University in Xi’an deciphered the mechanism of ultra-long starvation tolerance in deep-sea isopods and provides an important paradigm for understanding how life balances growth and survival in extreme environments.

The deep sea is cold, dark, and almost entirely devoid of reliable nutrition, making long-term survival a remarkable evolutionary feat. To survive the abyss, the isopod possesses an enormous stomach that occupies about two-thirds of its body and acts like a deep-freeze pantry, allowing it to gorge when food is available and store the haul for months or even years. Second, it maintains an exceptionally low basal metabolic rate, essentially putting itself on permanent energy-saving mode. Together, these traits turn opportunistic binge eating into an ultra-long energy reserve.

In addition, a key gene involved in this metabolic slowdown, named ND1, is not originally part of the isopod’s own genome. The isopod “hijacks” it from an external symbiotic bacterium through horizontal gene transfer.

To verify ND1’s function, the researchers inserted the gene into zebrafish, nematodes, and human cells in the lab. Under normal temperatures, the gene recipients burned energy faster and became less tolerant of starvation. However, under cold conditions that mimic the isopod’s deep-sea home, ND1 suppressed energy metabolism, reduced mitochondrial activity, and boosted starvation endurance in zebrafish by a remarkable 37 percent.

This temperature-dependent switch solves the so-called “energy paradox” — how can a giant animal with high energy demands survive where food is extremely scarce? The ND1 acts as a metabolic thermostat, fine-tuning energy burn in response to environmental conditions. It provides a solution to the trade-off between body size and food scarcity.

http://english.cas.cn/newsroom/research-news/202606/t20260608_1161380.shtml

https://onlinelibrary.wiley.com/doi/10.1002/mlf2.70089

Researchers from the CAS Qingdao Institute of Bioenergy and Bioprocess Technology (QIBEBT) and Shenzhen Third People’s Hospital have developed a Ramanome-based phenotypic platform to improve the efficiency of bacteriophage evaluation for potential clinical use.

By combining Raman spectroscopy with a random forest model, the researchers introduced the Ramanome-based Phage Susceptibility Test (RPST). This phenotypic method reduces the turnaround time for host range verification to approximately one hour, compared to the 11–21 hours typically required by traditional plaque-based assays.

Bacteriophages offer a precise alternative to antibiotics in the fight against antimicrobial resistance. However, matching phages to clinical bacterial isolates remains challenging due to their narrow host ranges and the slow, qualitative nature of conventional assays.

The RPST framework monitors bacterial metabolic changes within 40 minutes of phage-host co-incubation and identifies four conserved Raman spectral biomarker regions linked to nucleic acids, proteins, and lipids. Combining these biomarkers into a Composite Infection Index (CII), the system achieved a 96.0% concordance rate across 25 phage-host pairs.

Unlike static assays, the continuous CII metric estimates the fraction of infected cells, enabling researchers to rank phage potency and determine the minimum MOI required to sustain infection.

While the method shows operational promise, the researchers acknowledge the need for large-scale, multi-center validation across different instruments to ensure long-term clinical reproducibility.

Back to …